172 related articles for article (PubMed ID: 23669799)
21. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
22. How to prevent allopurinol hypersensitivity reactions?
Stamp LK; Barclay ML
Rheumatology (Oxford); 2018 Jan; 57(suppl_1):i35-i41. PubMed ID: 29272508
[TBL] [Abstract][Full Text] [Related]
23. Opportunities for improving medication use and monitoring in gout.
Singh JA; Hodges JS; Asch SM
Ann Rheum Dis; 2009 Aug; 68(8):1265-70. PubMed ID: 18701554
[TBL] [Abstract][Full Text] [Related]
24. Safety and efficacy of febuxostat treatment in subjects with gout and severe allopurinol adverse reactions.
Chohan S
J Rheumatol; 2011 Sep; 38(9):1957-9. PubMed ID: 21724706
[TBL] [Abstract][Full Text] [Related]
25. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease.
Panomvana D; Sripradit S; Angthararak S
J Clin Rheumatol; 2008 Feb; 14(1):6-11. PubMed ID: 18431090
[TBL] [Abstract][Full Text] [Related]
26. Urate-lowering therapy for gout: focus on febuxostat.
Love BL; Barrons R; Veverka A; Snider KM
Pharmacotherapy; 2010 Jun; 30(6):594-608. PubMed ID: 20500048
[TBL] [Abstract][Full Text] [Related]
27. Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012.
Ramasamy SN; Korb-Wells CS; Kannangara DR; Smith MW; Wang N; Roberts DM; Graham GG; Williams KM; Day RO
Drug Saf; 2013 Oct; 36(10):953-80. PubMed ID: 23873481
[TBL] [Abstract][Full Text] [Related]
28. Allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis.
Lee HY; Pang SM; Thamotharampillai T
J Am Acad Dermatol; 2008 Aug; 59(2):352-3. PubMed ID: 18638633
[No Abstract] [Full Text] [Related]
29. Examining the use of allopurinol: Perspectives from recent drug injury relief applications.
Huang CH; Chu MP; Chen WW
J Formos Med Assoc; 2019 Jan; 118(1 Pt 2):371-377. PubMed ID: 29941331
[TBL] [Abstract][Full Text] [Related]
30. [Fatal liver necrosis due to allopurinol].
Pereira S; Almeida J; Silva AO; Quintas M; Candeias O; Freitas F
Acta Med Port; 1998 Dec; 11(12):1141-4. PubMed ID: 10192993
[TBL] [Abstract][Full Text] [Related]
31. Allopurinol hypersensitivity syndrome in patients with hematological malignancies: characteristics and clinical outcomes.
Min HK; Lee B; Kwok SK; Ju JH; Kim WU; Park YM; Park SH
Korean J Intern Med; 2015 Jul; 30(4):521-30. PubMed ID: 26161019
[TBL] [Abstract][Full Text] [Related]
32. Factors associated with acute gout attacks in normouricaemic gout patients receiving allopurinol: a retrospective study.
So MW; Lee SG; Kim YG; Lee CK; Yoo B
Scand J Rheumatol; 2011 Nov; 40(6):444-7. PubMed ID: 21916803
[TBL] [Abstract][Full Text] [Related]
33. Allopurinol--dose according to effect, not renal function.
Bryant L
J Prim Health Care; 2011 Dec; 3(4):323. PubMed ID: 22235497
[No Abstract] [Full Text] [Related]
34. Efficacy and tolerability of urate-lowering drugs in gout: a randomised controlled trial of benzbromarone versus probenecid after failure of allopurinol.
Reinders MK; van Roon EN; Jansen TL; Delsing J; Griep EN; Hoekstra M; van de Laar MA; Brouwers JR
Ann Rheum Dis; 2009 Jan; 68(1):51-6. PubMed ID: 18250112
[TBL] [Abstract][Full Text] [Related]
35. The efficacy of combined low dose of Allopurinol and benzbromarone compared to standard dose of Allopurinol in hyperuricemia.
Akkasilpa S; Osiri M; Deesomchok U; Avihingsanon Y
J Med Assoc Thai; 2004 Sep; 87(9):1087-91. PubMed ID: 15516011
[TBL] [Abstract][Full Text] [Related]
36. [Fatal outcome in allopurinol hypersensitivity syndrome].
Kluger E
Ugeskr Laeger; 1998 Feb; 160(8):1179-80. PubMed ID: 9492630
[TBL] [Abstract][Full Text] [Related]
37. [How to select and use urate lowering agents for hyperuricemia].
Yamanaka H
Nihon Rinsho; 1996 Dec; 54(12):3261-5. PubMed ID: 8976102
[TBL] [Abstract][Full Text] [Related]
38. Febuxostat: new drug. Hyperuricaemia: risk of gout attacks.
Prescrire Int; 2009 Apr; 18(100):63-5. PubMed ID: 19585722
[TBL] [Abstract][Full Text] [Related]
39. Correction of allopurinol dosing should be based on clearance of creatinine, but not plasma creatinine levels: another insight to allopurinol-related toxicity.
Perez-Ruiz F; Hernando I; Villar I; Nolla JM
J Clin Rheumatol; 2005 Jun; 11(3):129-33. PubMed ID: 16357730
[TBL] [Abstract][Full Text] [Related]
40. [A case of vanishing bile duct syndrome associated with hypersensitivity to allopurinol].
Choi SH; Yang SH; Song YB; Kim HJ; Seo YT; Choi DS; Moon KH; Byun JH; Yu ES
Korean J Hepatol; 2005 Mar; 11(1):80-5. PubMed ID: 15788888
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
